Search

Your search keyword '"Ratziu, Vlad"' showing total 1,715 results
Start Over Author "Ratziu, Vlad"
1,715 results on '"Ratziu, Vlad"'

151. Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis

Author

Hoffmann, Céline, Djerir, Nour El Houda, Danckaert, Anne, Fernandes, Julien, Roux, Pascal, Charrueau, Christine, Lachagès, Anne-Marie, Charlotte, Frédéric, Brocheriou, Isabelle, Clément, Karine, Aron-Wisnewsky, Judith, Foufelle, Fabienne, Ratziu, Vlad, Hainque, Bernard, Bonnefont-Rousselot, Dominique, Bigey, Pascal, and Escriou, Virginie

Published
2020
Full Text
View/download PDF

153. Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study

Author

Lemoine, Maud, Assoumou, Lambert, De Wit, Stephane, Girard, Pierre-Marie, Valantin, Marc Antoine, Katlama, Christine, Necsoi, Coca, Campa, Pauline, Huefner, Anja D., Schulze zur Wiesch, Julian, Rougier, Hayette, Bastard, Jean-Philippe, Stocker, Hartmut, Mauss, Stefan, Serfaty, Lawrence, Ratziu, Vlad, Menu, Yves, Schlue, Jerome, Behrens, Georg, Bedossa, Pierre, Capeau, Jacqueline, Ingiliz, Patrick, and Costagliola, Dominique

Published
2018
Full Text
View/download PDF

155. Adlercreutzia equolifaciens Is an Anti-inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

Author

Plaza-Onate, Florian, primary, Chamignon, Célia, additional, Burz, Sebastian, additional, Lapaque, Nicolas, additional, Monnoye, Magali, additional, Philippe, Catherine, additional, Bredel, Maxime, additional, Chêne, Laurent, additional, Farin, William, additional, Paillarse, Jean-Michel, additional, Boursier, Jérome, additional, Ratziu, Vlad, additional, Mousset, Pierre-Yves, additional, Doré, Joël, additional, Gérard, Philippe, additional, and Blottière, Hervé M., additional

Published
2023
Full Text
View/download PDF

157. The endoplasmic reticulum stress sensor IRE1 regulates collagen secretion through the enforcement of the proteostasis factor P4HB/PDIA1 contributing to liver damage and fibrosis

Author

Hazari, Younis, primary, Urra, Hery, additional, Lopez, Valeria A. Garcia, additional, Diaz, Javier, additional, Tamburini, Giovanni, additional, Milani, Mateus, additional, Pihan, Philippe, additional, Durand, Sylvere, additional, Aprahamia, Fanny, additional, Baxter, Reese, additional, Huang, Menghao, additional, Dong, X Charlie, additional, Vihinen, Helena, additional, Gonzalez, Ana Batista, additional, Godoy, Patricio, additional, Criollo, Alfredo, additional, Ratziu, Vlad, additional, Foufelle, Fabienne, additional, Hengstler, Jan G., additional, Jokitalo, Eija, additional, Maitre, Beatrice Bailly, additional, Maiers, Jessica L, additional, Plate, Lars, additional, Kroemer, Guido, additional, and Hetz, Claudio, additional

Published
2023
Full Text
View/download PDF

158. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]

Author

Anstee, Quentin M., primary, Darlay, Rebecca, additional, Cockell, Simon, additional, Meroni, Marica, additional, Govaere, Olivier, additional, Tiniakos, Dina, additional, Burt, Alastair D., additional, Bedossa, Pierre, additional, Palmer, Jeremy, additional, Liu, Yang-Lin, additional, Aithal, Guruprasad P., additional, Allison, Michael, additional, Yki-Järvinen, Hannele, additional, Vacca, Michele, additional, Dufour, Jean-Francois, additional, Invernizzi, Pietro, additional, Prati, Daniele, additional, Ekstedt, Mattias, additional, Kechagias, Stergios, additional, Francque, Sven, additional, Petta, Salvatore, additional, Bugianesi, Elisabetta, additional, Clement, Karine, additional, Ratziu, Vlad, additional, Schattenberg, Jörn M., additional, Valenti, Luca, additional, Day, Christopher P., additional, Cordell, Heather J., additional, and Daly, Ann K., additional

Published
2023
Full Text
View/download PDF

159. Correction: Genome-wide association study of non- alcoholic fatty liver and steatohepatitis in a histologically characterised cohort ( vol 73, pp 505-515 , 2020 )

Author

Anstee, Quentin M., Darlay, Rebecca, Cockell, Simon, Meroni, Marica, Govaere, Olivier, Tiniakos, Dina, Burt, Alastair D., Bedossa, Pierre, Palmer, Jeremy, Liu, Yang-Lin, Aithal, Guruprasad P., Allison, Michael, Yki-Jarvinen, Hannele, Vacca, Michele, Dufour, Jean-Francois, Invernizzi, Pietro, Prati, Daniele, Ekstedt, Mattias, Kechagias, Stergios, Francque, Sven, Petta, Salvatore, Bugianesi, Elisabetta, Clement, Karine, Ratziu, Vlad, Schattenberg, Joern M., Valenti, Luca, Day, Christopher P., Cordell, Heather J., Daly, Ann K., Anstee, Quentin M., Darlay, Rebecca, Cockell, Simon, Meroni, Marica, Govaere, Olivier, Tiniakos, Dina, Burt, Alastair D., Bedossa, Pierre, Palmer, Jeremy, Liu, Yang-Lin, Aithal, Guruprasad P., Allison, Michael, Yki-Jarvinen, Hannele, Vacca, Michele, Dufour, Jean-Francois, Invernizzi, Pietro, Prati, Daniele, Ekstedt, Mattias, Kechagias, Stergios, Francque, Sven, Petta, Salvatore, Bugianesi, Elisabetta, Clement, Karine, Ratziu, Vlad, Schattenberg, Joern M., Valenti, Luca, Day, Christopher P., Cordell, Heather J., and Daly, Ann K.

Abstract

Funding Agencies|Economic and Social Research Council

Published
2023
Full Text
View/download PDF

160. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Author

Mary E, R, Jeffrey V, L, Vlad, R, Sven M, F, Arun J, S, Fasiha, K, Diana, R, Manal F, A, Quentin M, A, Juan Pablo, A, Marco, A, Ramon, B, Ulrich, B, Jerome, B, Elisabetta, B, Christopher, B, Graciela E, C, Abhijit, C, Helena, C, Donna, C, Kenneth, C, Mohamed, E, Samuel, K, Wayne, E, Jiangao, F, Samer, G, Cynthia D, G, Stephen A, H, Seung Up, K, Bart, K, Marko, K, Kris, K, Florence, L, Rohit, L, Robert, M, Timothy R, M, Elisabeth, P, Michael, R, Manuel, R, Marcelo, S, Shivaram Prasad, S, Silvia C, S, C Wendy, S, Dina, T, Luca, V, Miriam B, V, Vincent, W, Stavra, X, Yusuf, Y, Zobair, Y, Ansley, H, Marcela, V, Newsome, NVeeral Ajmeral, P, Alazawi, W, Alkhatry, M, Alkhouri, N, Allen, A, Allison, M, Alswat, K, R Alvares-da-Silva, M, Alves-Bezerra, M, J Armstrong, M, Arufe, D, Aschner, P, Baffy, G, Bansal, M, Bedossa, P, Belfort, R, Berg, T, Berzigotti, A, Betel, M, Bianco, C, Brass, C, L Brosgart, C, Matthews Brunt, E, Buti, M, Caldwell, S, Carr, R, Casanovas, T, Castera, L, Caussy, C, Cerda, E, Chalasani, N, Kheong Chan, W, Charatcharoenwitthaya, P, Charlton, M, Cheung, A, Chiodi, D, Chung, R, Cohen, D, Corey, K, P Cotrim, H, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, De Ledinghen, V, Demir, M, Diaz, S, Mae Diehl, A, Dimmig, B, Dirchwolf, M, Duseja, A, Dvorak, K, Ekstedt, M, El Wakil, R, Lucía Ferraz, M, Friedman, S, Fuchs, M, Gastaldelli, A, Geerts, A, Geier, A, Girala, M, Goh, G, Goossens, N, Graupera, I, Hagström, H, Henry, Z, Hunyady, B, Hutchison, A, Isaacs, S, Jornayvaz, F, Kemp, C, Kile, D, Kim, W, Kleiner, D, Kohli, R, Kugelmas, M, Lavine, J, Lazo, M, Leite, N, Lozano, A, Luukkonen, P, Macedo, P, Mansour, D, Mantzoros, C, Marchesini, G, Marciano, S, Martinez, K, Vladimirova Mateva, L, M Mato, J, Mccary, A, Miele, L, Mikolasevic, I, Miller, V, Moreno, R, Moylan, C, Nakajima, A, Charles Nault, J, Norris, S, Noureddin, M, P Oliveira, C, Ong, A, Padilla, M, Pais, R, Panduro, A, K Panigrahi, M, Papatheodoridis, G, Pelusi, S, Pérez, M, Perez Escobar, J, Perseghin, G, Pessoa, M, Petta, S, Pinzani, M, Platon Lupsor, M, Rabiee, A, Romeo, S, Rotman, Y, Rowe, I, Salupere, R, Satapathy, S, M Schattenberg, J, Schaufert, W, Schnabl, B, Seim, L, Serfaty, L, Shapiro, D, K Singal, A, Skladany, L, Stefan, N, Stine, J, Sundaram, S, Svegliati-Baroni, G, Szabo, G, Tacke, F, Tanwandee, T, Targher, G, Terrault, N, Tetri, B, Thiele, M, Tisthammer, B, Torre Delgadillo, A, Trauner, M, Tsochatzis, E, Van Kleef, L, Van Mil, S, Vanwagner, L, Antonio Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Watt, K, Wattacheril, J, Wilkins, F, Willemse, J, Zekry, A, Zelber-Sagi, S, Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Philip NVeeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart, Elizabeth Matthews Brunt, Maria Buti, Steve Caldwell, Rotonya Carr, Teresa Casanovas, Laurent Castera, Cyrielle Caussy, Eira Cerda, Naga Chalasani, Wah Kheong Chan, Phunchai Charatcharoenwitthaya, Michael Charlton, Amanda Cheung, Daniela Chiodi, Ray Chung, David Cohen, Kathleen Corey, Helma P Cotrim, Javier Crespo, Anuradha Dassanayake, Nicholas Davidson, Robert De Knegt, Victor De Ledinghen, Münevver Demir, Sebastian Diaz, Anna Mae Diehl, Bruce Dimmig, Melisa Dirchwolf, Ajay Duseja, Karel Dvorak, Mattias Ekstedt, Reda El Wakil, María Lucía Ferraz, Scott Friedman, Michael Fuchs, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Marcos Girala, George Goh, Nicolas Goossens, Isabel Graupera, Hannes Hagström, Zachary Henry, Bela Hunyady, Alan Hutchison, Scott Isaacs, François Jornayvaz, Cynthia Kemp, Denise Kile, Won Kim, David Kleiner, Rohit Kohli, Marcelo Kugelmas, Joel Lavine, Mariana Lazo, Nathalie Leite, Adelina Lozano, Panu Luukkonen, Paula Macedo, Dina Mansour, Christos Mantzoros, Giulio Marchesini, Sebastián Marciano, Kim Martinez, Lyudmila Vladimirova Mateva, Jose M Mato, Alexis McCary, Luca Miele, Ivana Mikolasevic, Veronica Miller, Rosalba Moreno, Cynthia Moylan, Atsushi Nakajima, Jean Charles Nault, Suzanne Norris, Mazen Noureddin, C P Oliveira, Arlin Ong, Martín Padilla, Raluca Pais, Arturo Panduro, Manas K Panigrahi, George Papatheodoridis, Serena Pelusi, Marlene Pérez, Juanita Perez Escobar, Gianluca Perseghin, Mario Pessoa, Salvatore Petta, Massimo Pinzani, Monica Platon Lupsor, Atoosa Rabiee, Stefano Romeo, Yaron Rotman, Ian Rowe, Riina Salupere, Sanjaya Satapathy, Jörn M Schattenberg, Wendy Schaufert, Bernd Schnabl, Lynn Seim, Lawrence Serfaty, David Shapiro, Ashwani K Singal, Lubomir Skladany, Norbert Stefan, Jonathan Stine, Shikha Sundaram, Gianluca Svegliati-Baroni, Gyonzgi Szabo, Frank Tacke, Tawesak Tanwandee, Giovanni Targher, Norah Terrault, Brent Tetri, Maja Thiele, Baron Tisthammer, Aldo Torre Delgadillo, Michael Trauner, Emmanuel Tsochatzis, Laurens Van Kleef, Saskia Van Mil, Lisa VanWagner, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Kymberly Watt, Julia Wattacheril, Fonda Wilkins, José Willemse, Amany Zekry, Shira Zelber-Sagi, Mary E, R, Jeffrey V, L, Vlad, R, Sven M, F, Arun J, S, Fasiha, K, Diana, R, Manal F, A, Quentin M, A, Juan Pablo, A, Marco, A, Ramon, B, Ulrich, B, Jerome, B, Elisabetta, B, Christopher, B, Graciela E, C, Abhijit, C, Helena, C, Donna, C, Kenneth, C, Mohamed, E, Samuel, K, Wayne, E, Jiangao, F, Samer, G, Cynthia D, G, Stephen A, H, Seung Up, K, Bart, K, Marko, K, Kris, K, Florence, L, Rohit, L, Robert, M, Timothy R, M, Elisabeth, P, Michael, R, Manuel, R, Marcelo, S, Shivaram Prasad, S, Silvia C, S, C Wendy, S, Dina, T, Luca, V, Miriam B, V, Vincent, W, Stavra, X, Yusuf, Y, Zobair, Y, Ansley, H, Marcela, V, Newsome, NVeeral Ajmeral, P, Alazawi, W, Alkhatry, M, Alkhouri, N, Allen, A, Allison, M, Alswat, K, R Alvares-da-Silva, M, Alves-Bezerra, M, J Armstrong, M, Arufe, D, Aschner, P, Baffy, G, Bansal, M, Bedossa, P, Belfort, R, Berg, T, Berzigotti, A, Betel, M, Bianco, C, Brass, C, L Brosgart, C, Matthews Brunt, E, Buti, M, Caldwell, S, Carr, R, Casanovas, T, Castera, L, Caussy, C, Cerda, E, Chalasani, N, Kheong Chan, W, Charatcharoenwitthaya, P, Charlton, M, Cheung, A, Chiodi, D, Chung, R, Cohen, D, Corey, K, P Cotrim, H, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, De Ledinghen, V, Demir, M, Diaz, S, Mae Diehl, A, Dimmig, B, Dirchwolf, M, Duseja, A, Dvorak, K, Ekstedt, M, El Wakil, R, Lucía Ferraz, M, Friedman, S, Fuchs, M, Gastaldelli, A, Geerts, A, Geier, A, Girala, M, Goh, G, Goossens, N, Graupera, I, Hagström, H, Henry, Z, Hunyady, B, Hutchison, A, Isaacs, S, Jornayvaz, F, Kemp, C, Kile, D, Kim, W, Kleiner, D, Kohli, R, Kugelmas, M, Lavine, J, Lazo, M, Leite, N, Lozano, A, Luukkonen, P, Macedo, P, Mansour, D, Mantzoros, C, Marchesini, G, Marciano, S, Martinez, K, Vladimirova Mateva, L, M Mato, J, Mccary, A, Miele, L, Mikolasevic, I, Miller, V, Moreno, R, Moylan, C, Nakajima, A, Charles Nault, J, Norris, S, Noureddin, M, P Oliveira, C, Ong, A, Padilla, M, Pais, R, Panduro, A, K Panigrahi, M, Papatheodoridis, G, Pelusi, S, Pérez, M, Perez Escobar, J, Perseghin, G, Pessoa, M, Petta, S, Pinzani, M, Platon Lupsor, M, Rabiee, A, Romeo, S, Rotman, Y, Rowe, I, Salupere, R, Satapathy, S, M Schattenberg, J, Schaufert, W, Schnabl, B, Seim, L, Serfaty, L, Shapiro, D, K Singal, A, Skladany, L, Stefan, N, Stine, J, Sundaram, S, Svegliati-Baroni, G, Szabo, G, Tacke, F, Tanwandee, T, Targher, G, Terrault, N, Tetri, B, Thiele, M, Tisthammer, B, Torre Delgadillo, A, Trauner, M, Tsochatzis, E, Van Kleef, L, Van Mil, S, Vanwagner, L, Antonio Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Watt, K, Wattacheril, J, Wilkins, F, Willemse, J, Zekry, A, Zelber-Sagi, S, Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Philip NVeeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart, Elizabeth Matthews Brunt, Maria Buti, Steve Caldwell, Rotonya Carr, Teresa Casanovas, Laurent Castera, Cyrielle Caussy, Eira Cerda, Naga Chalasani, Wah Kheong Chan, Phunchai Charatcharoenwitthaya, Michael Charlton, Amanda Cheung, Daniela Chiodi, Ray Chung, David Cohen, Kathleen Corey, Helma P Cotrim, Javier Crespo, Anuradha Dassanayake, Nicholas Davidson, Robert De Knegt, Victor De Ledinghen, Münevver Demir, Sebastian Diaz, Anna Mae Diehl, Bruce Dimmig, Melisa Dirchwolf, Ajay Duseja, Karel Dvorak, Mattias Ekstedt, Reda El Wakil, María Lucía Ferraz, Scott Friedman, Michael Fuchs, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Marcos Girala, George Goh, Nicolas Goossens, Isabel Graupera, Hannes Hagström, Zachary Henry, Bela Hunyady, Alan Hutchison, Scott Isaacs, François Jornayvaz, Cynthia Kemp, Denise Kile, Won Kim, David Kleiner, Rohit Kohli, Marcelo Kugelmas, Joel Lavine, Mariana Lazo, Nathalie Leite, Adelina Lozano, Panu Luukkonen, Paula Macedo, Dina Mansour, Christos Mantzoros, Giulio Marchesini, Sebastián Marciano, Kim Martinez, Lyudmila Vladimirova Mateva, Jose M Mato, Alexis McCary, Luca Miele, Ivana Mikolasevic, Veronica Miller, Rosalba Moreno, Cynthia Moylan, Atsushi Nakajima, Jean Charles Nault, Suzanne Norris, Mazen Noureddin, C P Oliveira, Arlin Ong, Martín Padilla, Raluca Pais, Arturo Panduro, Manas K Panigrahi, George Papatheodoridis, Serena Pelusi, Marlene Pérez, Juanita Perez Escobar, Gianluca Perseghin, Mario Pessoa, Salvatore Petta, Massimo Pinzani, Monica Platon Lupsor, Atoosa Rabiee, Stefano Romeo, Yaron Rotman, Ian Rowe, Riina Salupere, Sanjaya Satapathy, Jörn M Schattenberg, Wendy Schaufert, Bernd Schnabl, Lynn Seim, Lawrence Serfaty, David Shapiro, Ashwani K Singal, Lubomir Skladany, Norbert Stefan, Jonathan Stine, Shikha Sundaram, Gianluca Svegliati-Baroni, Gyonzgi Szabo, Frank Tacke, Tawesak Tanwandee, Giovanni Targher, Norah Terrault, Brent Tetri, Maja Thiele, Baron Tisthammer, Aldo Torre Delgadillo, Michael Trauner, Emmanuel Tsochatzis, Laurens Van Kleef, Saskia Van Mil, Lisa VanWagner, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Kymberly Watt, Julia Wattacheril, Fonda Wilkins, José Willemse, Amany Zekry, and Shira Zelber-Sagi

Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmati

Published
2023

161. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

Author

Jenny, Lee, Max, Westphal, Yasaman, Vali, Jerome, Boursier, Salvatorre, Petta, Rachel, Ostroff, Leigh, Alexander, Yu, Chen, Celine, Fournier, Andreas, Geier, Sven, Francque, Kristy, Wonder, Dina, Tiniako, Pierre, Bedossa, Mike, Allison, Georgios, Papatheodoridi, Helena, Cortez-Pinto, Raluca, Pai, Jean-Francois, Dufour, Diana Julie, Leeming, Stephen, Harrison, Jeremy, Cobbold, Adriaan G, Holleboom, Hannele, Yki-Järvinen, Javier, Crespo, Mattias, Ekstedt, Guruprasad P, Aithal, Elisabetta, Bugianesi, Manuel, Romero-Gomez, Richard, Torstenson, Morten, Karsdal, Carla, Yuni, Jörn M, Schattenberg, Detlef, Schuppan, Vlad, Ratziu, Clifford, Bra, Kevin, Duffin, Koos, Zwinderman, Michael, Pavlide, Quentin M, Anstee, Patrick M, Bossuyt, Anstee, Quentin M., Daly, Ann K., Govaere, Olivier, Cockell, Simon, Tiniakos, Dina, Bedossa, Pierre, Burt, Alastair, Oakley, Fiona, Cordell, Heather J., Day, Christopher P., Wonders, Kristy, Missier, Paolo, Mcteer, Matthew, Vale, Luke, Oluboyede, Yemi, Breckons, Matt, Bossuyt, Patrick M., Zafarmand, Hadi, Vali, Yasaman, Lee, Jenny, Nieuwdorp, Max, Holleboom, Adriaan G., Verheij, Joanne, Ratziu, Vlad, Clément, Karine, Patino-Navarrete, Rafael, Pais, Raluca, Paradis, Valerie, Schuppan, Detlef, Schattenberg, Jörn M., Surabattula, Rambabu, Myneni, Sudha, Straub, Beate K., Vidal-Puig, Toni, Vacca, Michele, Rodrigues-Cuenca, Sergio, Allison, Mike, Kamzolas, Ioanni, Petsalaki, Evangelia, Campbell, Mark, Lelliott, Chris J., Davies, Susan, Orešič, Matej, Hyötyläinen, Tuulia, Mcglinchey, Aiden, Mato, Jose M., Millet, Óscar, Dufour, Jean-Françoi, Berzigotti, Annalisa, Masoodi, Mojgan, Pavlides, Michael, Harrison, Stephen, Neubauer, Stefan, Cobbold, Jeremy, Mozes, Ferenc, Akhtar, Salma, Olodo-Atitebi, Seliat, Banerjee, Rajarshi, Kelly, Matt, Shumbayawonda, Elizabeth, Dennis, Andrea, Andersson, Anneli, Wigley, Ioan, Romero-Gómez, Manuel, Gómez-González, Emilio, Ampuero, Javier, Castell, Javier, Gallego-Durán, Rocío, Fernández, Isabel, Montero-Vallejo, Rocío, Karsdal, Morten, Guldager Kring Rasmussen, Daniel, Leeming, Diana Julie, Sinisi, Antonia, Musa, Kishwar, Sandt, Estelle, Tonini, Manuela, Bugianesi, Elisabetta, Rosso, Chiara, Armandi, Angelo, Marra, Fabio, Gastaldelli, Amalia, Svegliati, Gianluca, Boursier, Jérôme, Francque, Sven, Vonghia, Luisa, Driessen, Ann, Ekstedt, Mattia, Kechagias, Stergio, Yki-Järvinen, Hannele, Porthan, Kimmo, Arola, Johanna, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Rodrigues, Cecilia M. P., Valenti, Luca, Pelusi, Serena, Petta, Salvatore, Pennisi, Grazia, Miele, Luca, Geier, Andrea, Trautwein, Christian, Aithal, Guruprasad P., Francis, Susan, Hockings, Paul, Schneider, Moritz, Newsome, Philip, Hübscher, Stefan, Wenn, David, Rosenquist, Christian, Trylesinski, Aldo, Mayo, Rebeca, Alonso, Cristina, Duffin, Kevin, Perfield, James W., Chen, Yu, Yunis, Carla, Tuthill, Theresa, Harrington, Magdalena Alicia, Miller, Melissa, Chen, Yan, Mcleod, Euan Jame, Ross, Trenton, Bernardo, Barbara, Schölch, Corinna, Ertle, Judith, Younes, Ramy, Oldenburger, Anouk, Ostroff, Rachel, Alexander, Leigh, Biegel, Hannah, Skalshøi Kjær, Mette, Mørch Harder, Lea, Davidsen, Peter, Mikkelsen, Lars Frii, Balp, Maria-Magdalena, Brass, Clifford, Jennings, Lori, Martic, Miljen, Löffler, Jürgen, Applegate, Dougla, Shankar, Sudha, Torstenson, Richard, Fournier-Poizat, Céline, Llorca, Anne, Kalutkiewicz, Michael, Pepin, Kay, Ehman, Richard, Horan, Gerald, Ho, Gideon, Tai, Dean, Chng, Elaine, Patterson, Scott D., Billin, Andrew, Doward, Lynda, Twiss, Jame, Thakker, Paresh, Landgren, Henrik, Lackner, Carolin, Gouw, Annette, Hytiroglou, Prodromos, Luca, Miele (ORCID:0000-0003-3464-0068), Jenny, Lee, Max, Westphal, Yasaman, Vali, Jerome, Boursier, Salvatorre, Petta, Rachel, Ostroff, Leigh, Alexander, Yu, Chen, Celine, Fournier, Andreas, Geier, Sven, Francque, Kristy, Wonder, Dina, Tiniako, Pierre, Bedossa, Mike, Allison, Georgios, Papatheodoridi, Helena, Cortez-Pinto, Raluca, Pai, Jean-Francois, Dufour, Diana Julie, Leeming, Stephen, Harrison, Jeremy, Cobbold, Adriaan G, Holleboom, Hannele, Yki-Järvinen, Javier, Crespo, Mattias, Ekstedt, Guruprasad P, Aithal, Elisabetta, Bugianesi, Manuel, Romero-Gomez, Richard, Torstenson, Morten, Karsdal, Carla, Yuni, Jörn M, Schattenberg, Detlef, Schuppan, Vlad, Ratziu, Clifford, Bra, Kevin, Duffin, Koos, Zwinderman, Michael, Pavlide, Quentin M, Anstee, Patrick M, Bossuyt, Anstee, Quentin M., Daly, Ann K., Govaere, Olivier, Cockell, Simon, Tiniakos, Dina, Bedossa, Pierre, Burt, Alastair, Oakley, Fiona, Cordell, Heather J., Day, Christopher P., Wonders, Kristy, Missier, Paolo, Mcteer, Matthew, Vale, Luke, Oluboyede, Yemi, Breckons, Matt, Bossuyt, Patrick M., Zafarmand, Hadi, Vali, Yasaman, Lee, Jenny, Nieuwdorp, Max, Holleboom, Adriaan G., Verheij, Joanne, Ratziu, Vlad, Clément, Karine, Patino-Navarrete, Rafael, Pais, Raluca, Paradis, Valerie, Schuppan, Detlef, Schattenberg, Jörn M., Surabattula, Rambabu, Myneni, Sudha, Straub, Beate K., Vidal-Puig, Toni, Vacca, Michele, Rodrigues-Cuenca, Sergio, Allison, Mike, Kamzolas, Ioanni, Petsalaki, Evangelia, Campbell, Mark, Lelliott, Chris J., Davies, Susan, Orešič, Matej, Hyötyläinen, Tuulia, Mcglinchey, Aiden, Mato, Jose M., Millet, Óscar, Dufour, Jean-Françoi, Berzigotti, Annalisa, Masoodi, Mojgan, Pavlides, Michael, Harrison, Stephen, Neubauer, Stefan, Cobbold, Jeremy, Mozes, Ferenc, Akhtar, Salma, Olodo-Atitebi, Seliat, Banerjee, Rajarshi, Kelly, Matt, Shumbayawonda, Elizabeth, Dennis, Andrea, Andersson, Anneli, Wigley, Ioan, Romero-Gómez, Manuel, Gómez-González, Emilio, Ampuero, Javier, Castell, Javier, Gallego-Durán, Rocío, Fernández, Isabel, Montero-Vallejo, Rocío, Karsdal, Morten, Guldager Kring Rasmussen, Daniel, Leeming, Diana Julie, Sinisi, Antonia, Musa, Kishwar, Sandt, Estelle, Tonini, Manuela, Bugianesi, Elisabetta, Rosso, Chiara, Armandi, Angelo, Marra, Fabio, Gastaldelli, Amalia, Svegliati, Gianluca, Boursier, Jérôme, Francque, Sven, Vonghia, Luisa, Driessen, Ann, Ekstedt, Mattia, Kechagias, Stergio, Yki-Järvinen, Hannele, Porthan, Kimmo, Arola, Johanna, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Rodrigues, Cecilia M. P., Valenti, Luca, Pelusi, Serena, Petta, Salvatore, Pennisi, Grazia, Miele, Luca, Geier, Andrea, Trautwein, Christian, Aithal, Guruprasad P., Francis, Susan, Hockings, Paul, Schneider, Moritz, Newsome, Philip, Hübscher, Stefan, Wenn, David, Rosenquist, Christian, Trylesinski, Aldo, Mayo, Rebeca, Alonso, Cristina, Duffin, Kevin, Perfield, James W., Chen, Yu, Yunis, Carla, Tuthill, Theresa, Harrington, Magdalena Alicia, Miller, Melissa, Chen, Yan, Mcleod, Euan Jame, Ross, Trenton, Bernardo, Barbara, Schölch, Corinna, Ertle, Judith, Younes, Ramy, Oldenburger, Anouk, Ostroff, Rachel, Alexander, Leigh, Biegel, Hannah, Skalshøi Kjær, Mette, Mørch Harder, Lea, Davidsen, Peter, Mikkelsen, Lars Frii, Balp, Maria-Magdalena, Brass, Clifford, Jennings, Lori, Martic, Miljen, Löffler, Jürgen, Applegate, Dougla, Shankar, Sudha, Torstenson, Richard, Fournier-Poizat, Céline, Llorca, Anne, Kalutkiewicz, Michael, Pepin, Kay, Ehman, Richard, Horan, Gerald, Ho, Gideon, Tai, Dean, Chng, Elaine, Patterson, Scott D., Billin, Andrew, Doward, Lynda, Twiss, Jame, Thakker, Paresh, Landgren, Henrik, Lackner, Carolin, Gouw, Annette, Hytiroglou, Prodromos, and Luca, Miele (ORCID:0000-0003-3464-0068)

Abstract

Background and aims: Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD. Approach and results: Learning data were collected in the Liver Investigation: Testing Marker Utility in Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH CRN. Conditions of interest were the clinical trial definition of NASH (NAS ≥ 4;53%), at-risk NASH (NASH with F ≥ 2;35%), significant (F ≥ 2;47%), and advanced fibrosis (F ≥ 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputations. Data were randomly split into training/validation (75/25) sets. A gradient boosting machine was applied to develop 2 models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models.Clinical gradient boosting machine models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82). Conclusions: Detection of NASH and at-risk NASH can be improved by constructing independent machine learning models for each component, using only clinical predictors. Adding biomarkers only improved the accuracy of fibrosis.

Published
2023

162. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kri, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, Miele, Luca, NAFLD Nomenclature consensus, Group, Miele, Luca (ORCID:0000-0003-3464-0068), Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kri, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, Miele, Luca, NAFLD Nomenclature consensus, Group, and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

Unlabelled: The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. Methods: A modified Delphi process was led by three large pan-national liver associations. Consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. Results: A total of 236 panellists from 56 countries participated in four online surveys and two hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83% and 78%, respectively. 74% of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms 'non-alcoholic' and 'fatty' were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease (SLD) was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least one of five cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic SLD. A new category, outside pure MASLD, termed MetALD was selected to describe those with MASLD who consume greater amounts of alcohol per week (140 to 350 g/week and 210 to 420 g/week for females and males respectively). Conclusions: The new nomenclature and diagnostic criteria are widely supported, non-stigmatising and can improve awareness and patient identification.

Published
2023

163. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

Author

Lee, Jenny, Westphal, Max, Vali, Yasaman, Boursier, Jerome, Petta, Salvatorre, Ostroff, Rachel, Alexander, Leigh, Chen, Yu, Fournier, Celine, Geier, Andreas, Francque, Sven, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-Francois, Leeming, Diana Julie, Harrison, Stephen, Cobbold, Jeremy, Holleboom, Adriaan G., Yki-Jarvinen, Hannele, Crespo, Javier, Ekstedt, Mattias, Aithal, Guruprasad P., Bugianesi, Elisabetta, Romero-Gomez, Manuel, Torstenson, Richard, Karsdal, Morten, Yunis, Carla, Schattenberg, Joern M., Schuppan, Detlef, Ratziu, Vlad, Brass, Clifford, Duffin, Kevin, Zwinderman, Koos, Pavlides, Michael, Anstee, Quentin M., Bossuyt, Patrick M., LITMUS Investigators, Lee, Jenny, Westphal, Max, Vali, Yasaman, Boursier, Jerome, Petta, Salvatorre, Ostroff, Rachel, Alexander, Leigh, Chen, Yu, Fournier, Celine, Geier, Andreas, Francque, Sven, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-Francois, Leeming, Diana Julie, Harrison, Stephen, Cobbold, Jeremy, Holleboom, Adriaan G., Yki-Jarvinen, Hannele, Crespo, Javier, Ekstedt, Mattias, Aithal, Guruprasad P., Bugianesi, Elisabetta, Romero-Gomez, Manuel, Torstenson, Richard, Karsdal, Morten, Yunis, Carla, Schattenberg, Joern M., Schuppan, Detlef, Ratziu, Vlad, Brass, Clifford, Duffin, Kevin, Zwinderman, Koos, Pavlides, Michael, Anstee, Quentin M., Bossuyt, Patrick M., and LITMUS Investigators

Abstract

Background and Aims: Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F >= 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD. Approach and Results: Learning data were collected in the Liver Investigation: Testing Marker Utility in Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH CRN. Conditions of interest were the clinical trial definition of NASH (NAS >= 4;53%), at-risk NASH (NASH with F >= 2;35%), significant (F >= 2;47%), and advanced fibrosis (F >= 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputations. Data were randomly split into training/validation (75/25) sets. A gradient boosting machine was applied to develop 2 models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models.Clinical gradient boosting machine models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82). Conclusions: Detection of NASH and at-risk NASH can be improved by constructing independent machine learning models for each component, using only clinical predictors. Adding biomarkers only improved the accuracy of fibrosis., Funding Agencies|Jenny Lee, Quentin M. Anstee, and Pierre Bedossa conceptualized and designed the study; Jerome Boursier, Salvatore Petta, Kristy Wonders, Dina Tiniakos, Pierre Bedossa, Andreas Geier, Sven Francque, Mike Allison, Georgios Papatheodoridis, Helena Cortez-Pin

Published
2023
Full Text
View/download PDF

164. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

Author

Innovative Medicines Initiative, European Commission, Research Foundation - Flanders, Lee, Jenny, Westphal, Max, Vali, Yasaman, Boursier, Jerome, Petta, Salvatorre, Ostroff, Rachel, Alexander, Leigh, Chen, Yu, Fournier, Celine, Geier, Andreas, Francque, Sven, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-François, Leeming, Diana Julie, Harrison, Stephen, Cobbold, Jeremy, Holleboom, Adriaan G., Yki-Järvinen, Hannele, Crespo, Javier, Ekstedt, Mattias, Aithal, Guruprasad P., Bugianesi, Elisabetta, Romero-Gómez, Manuel, Torstenson, Richard, Karsdal, Morten, Yunis, Carla27, Schattenberg, Jörn M., Schuppan, Detlef, Ratziu, Vlad, Brass, Clifford, Duffin, Kevin, Zwinderman, Koos, Pavlides, Michael, Anstee, Quentin M., Bossuyt, Patrick M., LITMUS investigators, Innovative Medicines Initiative, European Commission, Research Foundation - Flanders, Lee, Jenny, Westphal, Max, Vali, Yasaman, Boursier, Jerome, Petta, Salvatorre, Ostroff, Rachel, Alexander, Leigh, Chen, Yu, Fournier, Celine, Geier, Andreas, Francque, Sven, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-François, Leeming, Diana Julie, Harrison, Stephen, Cobbold, Jeremy, Holleboom, Adriaan G., Yki-Järvinen, Hannele, Crespo, Javier, Ekstedt, Mattias, Aithal, Guruprasad P., Bugianesi, Elisabetta, Romero-Gómez, Manuel, Torstenson, Richard, Karsdal, Morten, Yunis, Carla27, Schattenberg, Jörn M., Schuppan, Detlef, Ratziu, Vlad, Brass, Clifford, Duffin, Kevin, Zwinderman, Koos, Pavlides, Michael, Anstee, Quentin M., Bossuyt, Patrick M., and LITMUS investigators

Abstract

[Background and Aims] Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD., [Approach and Results] Learning data were collected in the Liver Investigation: Testing Marker Utility in Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH CRN. Conditions of interest were the clinical trial definition of NASH (NAS ≥ 4;53%), at-risk NASH (NASH with F ≥ 2;35%), significant (F ≥ 2;47%), and advanced fibrosis (F ≥ 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputations. Data were randomly split into training/validation (75/25) sets. A gradient boosting machine was applied to develop 2 models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models. Clinical gradient boosting machine models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82)., [Conclusions] Detection of NASH and at-risk NASH can be improved by constructing independent machine learning models for each component, using only clinical predictors. Adding biomarkers only improved the accuracy of fibrosis.

Published
2023

165. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Author

Innovative Medicines Initiative, European Commission, Vali, Yasaman, Lee, Jenny, Boursier, Jerome, Petta, Salvatore, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Geier, Andreas, Francque, Sven, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-François, Leeming, Diana Julie, Harrison, Stephen A., Chen, Yu, Cobbold, Jeremy F., Pavlides, Michael, Holleboom, Adriaan G., Yki-Jarvinen, Hannele, Crespo, Javier, Karsdal, Morten, Ostroff, Rachel, Zafarmand, Mohammad Hadi, Torstenson, Richard, Duffin, Kevin, Yunis, Carla, Brass, Clifford, Ekstedt, Mattias, Aithal, Guruprasad P., Schattenberg, Jörn M., Bugianesi, Elisabetta, Romero-Gómez, Manuel, Ratziu, Vlad, Anstee, Quentin M., Bossuyt, Patrick M., on behalf of theLiver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators, Innovative Medicines Initiative, European Commission, Vali, Yasaman, Lee, Jenny, Boursier, Jerome, Petta, Salvatore, Wonders, Kristy, Tiniakos, Dina, Bedossa, Pierre, Geier, Andreas, Francque, Sven, Allison, Mike, Papatheodoridis, Georgios, Cortez-Pinto, Helena, Pais, Raluca, Dufour, Jean-François, Leeming, Diana Julie, Harrison, Stephen A., Chen, Yu, Cobbold, Jeremy F., Pavlides, Michael, Holleboom, Adriaan G., Yki-Jarvinen, Hannele, Crespo, Javier, Karsdal, Morten, Ostroff, Rachel, Zafarmand, Mohammad Hadi, Torstenson, Richard, Duffin, Kevin, Yunis, Carla, Brass, Clifford, Ekstedt, Mattias, Aithal, Guruprasad P., Schattenberg, Jörn M., Bugianesi, Elisabetta, Romero-Gómez, Manuel, Ratziu, Vlad, Anstee, Quentin M., Bossuyt, Patrick M., and on behalf of theLiver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators

Abstract

[Background] The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in a single cohort. As part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, we aimed to evaluate the diagnostic accuracy of 17 biomarkers and multimarker scores in detecting NASH and clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and identify their optimal cutoffs as screening tests in clinical trial recruitment., [Methods] This was a comparative diagnostic accuracy study in people with biopsy-confirmed NAFLD from 13 countries across Europe, recruited between Jan 6, 2010, and Dec 29, 2017, from the LITMUS metacohort of the prospective European NAFLD Registry. Adults (aged ≥18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence of other chronic liver diseases were excluded. The diagnostic accuracy of the biomarkers was expressed as the area under the receiver operating characteristic curve (AUC) with liver histology as the reference standard and compared with the Fibrosis-4 index for liver fibrosis (FIB-4) in the same subgroup. Target conditions were the presence of NASH with clinically significant fibrosis (ie, at-risk NASH; NAFLD Activity Score ≥4 and F≥2) or the presence of advanced fibrosis (F≥3), analysed in all participants with complete data. We identified thres holds for each biomarker for reducing the number of biopsy-based screen failures when recruiting people with both NASH and clinically significant fibrosis for future trials., [Findings] Of 1430 participants with NAFLD in the LITMUS metacohort with serum samples, 966 (403 women and 563 men) were included after all exclusion criteria had been applied. 335 (35%) of 966 participants had biopsy-confirmed NASH and clinically significant fibrosis and 271 (28%) had advanced fibrosis. For people with NASH and clinically significant fibrosis, no single biomarker or multimarker score significantly reached the predefined AUC 0·80 acceptability threshold (AUCs ranging from 0·61 [95% CI 0·54–0·67] for FibroScan controlled attenuation parameter to 0·81 [0·75–0·86] for SomaSignal), with accuracy mostly similar to FIB-4. Regarding detection of advanced fibrosis, SomaSignal (AUC 0·90 [95% CI 0·86–0·94]), ADAPT (0·85 [0·81–0·89]), and FibroScan liver stiffness measurement (0·83 [0·80–0·86]) reached acceptable accuracy. With 11 of 17 markers, histological screen failure rates could be reduced to 33% in trials if only people who were marker positive had a biopsy for evaluating eligibility. The best screening performance for NASH and clinically significant fibrosis was observed for SomaSignal (number needed to test [NNT] to find one true positive was four [95% CI 4–5]), then ADAPT (six [5–7]), MACK-3 (seven [6–8]), and PRO-C3 (nine [7–11])., [Interpretation] None of the single markers or multimarker scores achieved the predefined acceptable AUC for replacing biopsy in detecting people with both NASH and clinically significant fibrosis. However, several biomarkers could be applied in a prescreening strategy in clinical trial recruitment. The performance of promising markers will be further evaluated in the ongoing prospective LITMUS study cohort.

Published
2023

166. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal, Anstee, Quentin, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramón, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Castro Narro, Graciela E., Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N., on behalf of the NAFLD Nomenclature consensus group, Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal, Anstee, Quentin, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramón, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Castro Narro, Graciela E., Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N., and on behalf of the NAFLD Nomenclature consensus group

Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and c

Published
2023

169. Evaluation of PXL065 – Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1)

Author

Harrison, Stephen A., primary, Thang, Carole, additional, Bolze, Sébastien, additional, Dewitt, Sheila, additional, Hallakou-Bozec, Sophie, additional, Dubourg, Julie, additional, Bedossa, Pierre, additional, Cusi, Kenneth, additional, Ratziu, Vlad, additional, Grouin, Jean-Marie, additional, Moller, David E., additional, and Fouqueray, Pascale, additional

Published
2023
Full Text
View/download PDF

172. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases

Author

Grimaldi, André, Giral, Philippe, Bruckert, Eric, Basdevant, Arnaud, Clement, Karine, Oppert, Jean-Michel, Hartemann-Heurtier, Agnès, Andreelli, Fabrizio, Gombert, Sophie, Jacqueminet, Sophie, Cocaul, Arnaud, Fouffelle, Fabienne, Moussalli, Joseph, Thabut, Dominique, Lebray, Pascal, Podevin, Philippe, Bonnefont-Rousselot, Dominique, Bittar, Randa, Benhamou, Yves, Bernhardt, Carole, Boitard, Christian, Larger, Etienne, Sola, Agnès, El-Etr, Martine, Gautier, Jean-François, Serfaty, Lawrence, Housset, Chantal, Capeau, Jacqueline, Nascimbeni, Fabio, Fedchuk, Larysa, Oliveira, Claudia P., Alvares-da-Silva, Mario Reis, Varault, Anne, Ingiliz, Patrick, Ngo, Yen, de Torres, Mercedes, Munteanu, Mona, Poynard, Thierry, and Ratziu, Vlad

Published
2015
Full Text
View/download PDF

173. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Author

Rasmussen, Daniel Guldager Kring, primary, Anstee, Quentin M., additional, Torstenson, Richard, additional, Golding, Bruno, additional, Patterson, Scott D., additional, Brass, Clifford, additional, Thakker, Paresh, additional, Harrison, Stephen, additional, Billin, Andrew N., additional, Schuppan, Detlef, additional, Dufour, Jean-François, additional, Andersson, Anneli, additional, Wigley, Ioan, additional, Shumbayawonda, Elizabeth, additional, Dennis, Andrea, additional, Schoelch, Corinna, additional, Ratziu, Vlad, additional, Yunis, Carla, additional, Bossuyt, Patrick, additional, and Karsdal, Morten Asser, additional

Published
2022
Full Text
View/download PDF

174. From the Editor’s Desk…

Author

Burra, Patrizia, primary, Tacke, Frank, additional, Ratziu, Vlad, additional, Zeuzem, Stefan, additional, Sangro, Bruno, additional, and Angeli, Paolo, additional

Published
2022
Full Text
View/download PDF

177. RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease

Author

Afonso, Marta B., primary, Islam, Tawhidul, additional, Magusto, Julie, additional, Amorim, Ricardo, additional, Lenoir, Véronique, additional, Simões, Rui F., additional, Teixeira, José, additional, Silva, Liana C., additional, Wendum, Dominique, additional, Jéru, Isabelle, additional, Vigouroux, Corinne, additional, Castro, Rui E., additional, Oliveira, Paulo J., additional, Prip‐Buus, Carina, additional, Ratziu, Vlad, additional, Gautheron, Jérémie, additional, and Rodrigues, Cecília M. P., additional

Published
2022
Full Text
View/download PDF

182. 241 - Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial

Author

Nelson, Morag, Sanyal, Arun J, Bedossa, Pierre, Fraessdorf, Mandy, Neff, Guy W, Lawitz, Eric, Bugianesi, Elisabetta, Anstee, Quentin M, Hussain, Samina Ajaz, Newsome, Philip N, Ratziu, Vlad, Hosseini-Tabatabaei, Azadeh, Schattenberg, Joern M, Noureddin, Mazen, Alkhouri, Naim, and Younes, Ramy

Published
2024
Full Text
View/download PDF

183. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension

Author

Elkrief, Laure, Lazareth, Marie, Chevret, Sylvie, Paradis, Valérie, Magaz, Marta, Blaise, Lorraine, Rubbia‐Brandt, Laura, Moga, Lucile, Durand, François, Payancé, Audrey, Plessier, Aurélie, Chaffaut, Cendrine, Valla, Dominique, Malphettes, Marion, Diaz, Alba, Nault, Jean‐Charles, Nahon, Pierre, Audureau, Etienne, Ratziu, Vlad, Castera, Laurent, Garcia Pagan, Juan‐Carlos, Ganne‐Carrie, Nathalie, Rautou, Pierre‐Emmanuel, Marcellin, Patrick, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean‐Pierre, Zarski, Jean‐Pierre, Leroy, Vincent, Riachi, Ghassan, Calès, Paul, Péron, Jean‐Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean‐Frédéric, Abergel Olivier Chazouillères, Armand, Mallat, Ariane, Grangé, Jean‐Didier, Attali, Pierre, Bacq, Yannick, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen‐Khac, Eric, Bernard‐Chabert, Brigitte, Zucman, David, and Di Martino, Vincent

Subjects
0301 basic medicine, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Hepatitis C virus, Fatty liver, medicine.disease, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, Liver disease, 030104 developmental biology, 0302 clinical medicine, Esophageal varices, Internal medicine, Ascites, medicine, Portal hypertension, 030211 gastroenterology & hepatology, medicine.symptom, Transient elastography, business
Abstract

Background & aims Porto-sinusoidal vascular liver disease (PSVD) is a rare cause of portal hypertension. PSVD is still often misdiagnosed as cirrhosis, emphasizing the need to improve PSVD diagnosis strategies. Data on liver stiffness measurement (TE-LSM) using transient elastography, in PSVD are limited. The aim of this study was to evaluate the accuracy of TE-LSM to discriminate PSVD from cirrhosis in patients with signs of portal hypertension. Approach & results Retrospective multicenter study comparing TE-LSM in patients with PSVD, according to VALDIG criteria, to patients with compensated biopsy-proven cirrhosis related to alcohol (n=117), hepatitis C virus (HCV) infection (n=110) or non-alcoholic fatty liver disease (NAFLD) (n=46). All patients had at least one sign of portal hypertension among gastroesophageal varices, splenomegaly, porto-systemic collaterals, history of ascites or platelet count Conclusions This study including a total of 155 patients with PSVD and 273 patients with cirrhosis demonstrates that TE-LSM 20 kPa, PSVD is highly unlikely.

Published
2021

184. Clinical Trial Landscape in NASH.

Author

Harrison, Stephen A., Loomba, Rohit, Dubourg, Julie, Ratziu, Vlad, and Noureddin, Mazen

Abstract

Nonalcoholic fatty liver disease consists of a spectrum starting from nonalcoholic fatty liver disease that may progress to nonalcoholic steatohepatitis (NASH), which can lead to fibrosis, cirrhosis, hepatocellular carcinoma, or even liver failure. The prevalence of NASH has increased in parallel with the rising rate of obesity and type 2 diabetes. Given the high prevalence and deadly complications of NASH, there have been significant efforts to develop effective treatments. Phase 2A studies have assessed various mechanisms of action across the spectrum of the disease, while phase 3 studies have focused mainly on NASH and fibrosis stage 2 and higher, as these patients have a higher risk of disease morbidity and mortality. The primary efficacy endpoints also vary, by using noninvasive tests in early-phase trials while relying on liver histological endpoints in phase 3 studies as required by regulatory agencies. Despite initial disappointment due to the failure of several drugs, recent phase 2 and 3 studies have shown promising results, with the first Food and Drug Administration–approved drug for NASH expected to be approved in 2023. In this review, we discuss the various drugs under development for NASH, their mechanisms of action, and the results of their clinical trials. We also highlight the potential challenges in developing pharmacological therapies for NASH. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

186. Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

Author

Fontaine, Helene, primary, Fougerou-Leurent, Claire, additional, Gordien, Emmanuel, additional, Scholtes, Caroline, additional, Metivier, Sophie, additional, de Lédinghen, Victor, additional, Ratziu, Vlad, additional, Alric, Laurent, additional, Ganne-Carrié, Nathalie, additional, Loustaud-Ratti, Veronique, additional, Guyader, Dominique, additional, Leroy, Vincent, additional, Dumortier, Jérôme, additional, Lacombe, Karine, additional, Pageaux, Georges-Philippe, additional, Franza, Anne Minello, additional, Tual, Christelle, additional, Renault, Alain, additional, Le Pabic, Estelle, additional, Marchand, Lucie, additional, Roulot, Dominique, additional, and Zoulim, Fabien, additional

Published
2022
Full Text
View/download PDF

189. Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score

Author

Pai, Rish, primary, Jairath, Vipul, additional, Hogan, Malcolm, additional, Zou, Guangyong, additional, Adeyi, Oyedele, additional, Anstee, Quentin, additional, Aqel, Bashar, additional, Behling, Cynthia, additional, Carey, Elizabeth, additional, Clouston, Andrew, additional, Corey, Kathleen, additional, Feagan, Brian, additional, Kleiner, David E., additional, Ma, Christopher, additional, McFarlane, Stefanie, additional, Noureddin, Mazen, additional, Ratziu, Vlad, additional, Valasek, Mark, additional, Younossi, Zobair, additional, Harrison, Stephen, additional, and Loomba, Rohit, additional

Published
2022
Full Text
View/download PDF

193. Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Author

Loomba, Rohit, primary, Abdelmalek, Manal F., additional, Armstrong, Matthew, additional, Jara, Maximilian, additional, Kjaer, Mette, additional, Krarup, Niels, additional, Lawitz, Eric, additional, Ratziu, Vlad, additional, Sanyal, Arun, additional, Schattenberg, Jörn, additional, and Newsome, Philip N., additional

Published
2022
Full Text
View/download PDF

194. Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging

Author

Ratziu, Vlad, primary, Yılmaz, Yusuf, additional, Lazas, Don, additional, Friedman, Scott, additional, Lackner, Carolin, additional, Behling, Cynthia, additional, Cummings, Oscar, additional, Chen, Li, additional, Petitjean, Mathieu, additional, Gilgun-Sherki, Yossi, additional, Kadosh, Shaul, additional, and Sanyal, Arun, additional

Published
2022
Full Text
View/download PDF

197. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

Author

Zoulim, Fabien, Chulanov, Vladimir, Lampertico, Pietro, Wedemeyer, Heiner, Streinu-Cercel, Adrian, Pantea, Victor, Lazar, Stefan, Gherlan, George Sebastian, Bogomolov, Pavel, Stepanova, Tatyana, Morozov, Viacheslav, Syutkin, Vladimir, Sagalova, Olga, Manuilov, Dmitry, Mercier, Renee-Claude, Ye, Lei, Chee, Grace M., Da, Ben L., Lau, Audrey H., Osinusi, Anu, Bourliere, Marc, Ratziu, Vlad, Pol, Stanislas, Hilleret, Marie-Noëlle, and Asselah, Tarik

Published
2024
Full Text
View/download PDF

199. SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests

Author

Newsome, Philip N., Bugianesi, Elisabetta, Ratziu, Vlad, Rinella, Mary E., Roden, Michael, Engebretsen, Kristiane A., Kliers, Iris, Østergaard, Laura, Vanni, Denise, Zacho, Jeppe, and Sanyal, Arun J.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results